Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 16,600 shares, a growth of 9.2% from the October 15th total of 15,200 shares. Based on an average daily trading volume, of 12,200 shares, the short-interest ratio is presently 1.4 days. Currently, 0.3% of the company's shares are sold short.

Indaptus Therapeutics Price Performance

Shares of INDP traded down $0.07 during trading hours on Wednesday, reaching $1.66. The stock had a trading volume of 9,671 shares, compared to its average volume of 183,180. Indaptus Therapeutics has a 12 month low of $1.64 and a 12 month high of $7.10. The firm has a 50-day simple moving average of $2.13 and a 200 day simple moving average of $2.48.

Get Indaptus Therapeutics alerts:

Insiders Place Their Bets

In other Indaptus Therapeutics news, CEO Jeffrey A. Meckler purchased 10,308 shares of the business's stock in a transaction on Thursday, September 8th. The shares were purchased at an average cost of $2.80 per share, for a total transaction of $28,862.40. Following the acquisition, the chief executive officer now owns 65,374 shares of the company's stock, valued at $183,047.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 36.00% of the company's stock.

Hedge Funds Weigh In On Indaptus Therapeutics

A number of large investors have recently modified their holdings of INDP. Vanguard Group Inc. lifted its holdings in shares of Indaptus Therapeutics by 18.7% in the 1st quarter. Vanguard Group Inc. now owns 242,235 shares of the company's stock worth $969,000 after purchasing an additional 38,216 shares in the last quarter. Northern Trust Corp bought a new position in shares of Indaptus Therapeutics in the 1st quarter worth $41,000. State Street Corp bought a new position in shares of Indaptus Therapeutics in the 1st quarter worth $78,000. Renaissance Technologies LLC bought a new position in shares of Indaptus Therapeutics in the 2nd quarter worth $51,000. Finally, Strategy Asset Managers LLC bought a new position in Indaptus Therapeutics during the 3rd quarter valued at $120,000. 19.25% of the stock is currently owned by institutional investors.

Indaptus Therapeutics Company Profile

(Get Rating)

Indaptus Therapeutics, Inc, a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial.

Featured Articles

• Get a free copy of the StockNews.com research report on Indaptus Therapeutics (INDP)
• Why Lowe's Is Up And Home Depot Down
• The TJX Companies Could Break Out To New Highs
• Gold Rush: Newmont Corp. is Starting to Sparkle
• Four Healthcare Stocks To Watch This Week
• Will It Be Smooth Sailing For Carnival After 56% One-Month Rally?

Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.